Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NTRK Gene fusion banner

This section contains information and education for healthcare professionals and has been developed as a comprehensive resource providing information on TRK fusion proteins as a potential therapeutic target for selected patients across multiple tumour types.
This section was created in 2019 and updated in 2022.

There are three modules in this section. They are aimed at medical oncologists and pathologists including molecular and surgical pathologists. Geneticists, pharmacists, and public health professionals may also find this information useful. We recommend that Module 1 is selected first, but the modules can be selected in any order.

Find more about aims of this section, learning outcomes, expert contributors and other general information.

By pursuing, you confirm that you have read and understand the disclaimer.


Last updated: June 2022

Overview of NTRK Gene Fusion in specific tumours

This module focuses on specific tumour types including, lung, gastrointestinal (GI) and thyroid tumours and sarcomas, where NTRK gene fusions are relatively prevalent, and more awareness is warranted regarding the use of NTRK targeting agents.

Read more

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.